Lianyuhui Secures ￥100 Million in Series C Funding

(VCBeat) Feb. 16, 2021 -- Lianyuhui, an innovative digital medical platform in the field of oncology, today announced it has raised more than 100 million yuan in Series C funding, led by Qiming Venture Partners, with participation from DT Capital Partners, old shareholders, Wang Jiaquan Family Office, Yuanju Capital and existing investors including Redhill Capital and Juhe Capital. Haoyue Capital served as the exclusive financial adviser for the latest round.

Founded in 2015, Liangyihui is an online medicine and therapeutic information service platform in oncology and the official platform cooperating with the Chinese Society of Clinical Oncology (CSCO). The company has long-term and in-depth cooperation with many well-known hospitals and authoritative institutions at home and abroad. 

Liangyihui is committed to solving the information asymmetry in the field of oncology. The company provides professional knowledge and efficient tools for oncologists to improve diagnosis and treatment and offers services such as the popularization of science, medical guidance, diagnosis, and treatment to cancer patients.

Liangyihui has reached the largest number of online oncology doctors and patients, with nearly 200,000 oncologists and nearly 300,000 oncology patients currently active on its platform. At the same time, the group has been deeply cooperated with various cancer hospitals to help them educate and manage patients. After 6 years of experience from content-driven, to technological innovation and data-driven, Liangyihui has become the preferred online platform for oncology doctors and patients.

In the future, based on the application scenarios of digital medicine in oncology, Liangyihui will make efforts to meet the medical needs of oncology doctors and patients, combining with its own Internet hospital, and develop into an innovative digital medical service platform for pharmaceutical companies, doctors, hospitals and patients.

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Shenzhen, Hong Kong, Seattle, Boston, and San Francisco Bay Area. Currently, Qiming Venture Partners manages seven US Dollar funds and five RMB funds with over US$4 billion assets under management. Qiming Venture Partners invests in information technology, new consumer business patterns, and the healthcare sector.

Founded in 2006 and based in Shanghai, China, DT Capital Partners is a private equity investment firm that provides growth capital to early and expansion-stage companies. They invest in dynamic businesses that have high growth potential, strong management teams, and demonstrated revenue models in both technology-based and traditional industries.